BioCentury
ARTICLE | Clinical News

Ipsen reports data for Somatuline Autogel

July 11, 2013 11:52 PM UTC

Ipsen Group (Euronext:IPN; Pink:IPSEY) said subcutaneous Somatuline Autogel given every four weeks for up to 96 weeks met the primary endpoint of improving progression-free survival (PFS) vs. placebo in the Phase III CLARINET trial to treat non-functioning gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs). The double-blind, international trial enrolled 204 patients with well or moderately differentiated non-functioning GEP-NETs. Data will be presented at the European Society for Medical Oncology meeting in September.

Ipsen declined to disclose next steps for the indication. The company markets the extended-release formulation of somatostatin analog lanreotide as Somatuline Depot in the U.S. to treat acromegaly and in the EU as Somatuline Autogel to treat acromegaly and neuroendocrine tumors. ...